{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T12:08:00.086257+00:00","company":{"ticker":"TBPH","cik":1583107,"company_name":"Theravance Biopharma, Inc."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"485063c3cb43b35521de8a402f4d1f8a1d407be7","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-05-07T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter of 2026","report_date":"2026-05-07","result_type":"reported_results","revenue_text":"$17.7 million"},"claim":"Theravance Biopharma, Inc. reported first quarter of 2026 results: revenue $17.7 million.","evidence_excerpt":"Total revenue for the first quarter of 2026 was $17.7 million, consisting entirely of Viatris collaboration revenue.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-26-056733","anchor_url":"https://secwatch.observer/filing/0001104659-26-056733#claim-485063c3cb43b35521de8a402f4d1f8a1d407be7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926056733/0001104659-26-056733-index.htm"},{"fact_type":"restructuring_charge","fact_key":"d9246ac14ae0aaac8a8523e6076bc8c927fb1ee5","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2026-03-03T23:59:59+00:00","payload":{"affected_area":"R&D and G&A functions","charge_text":"approximately $5 million to $7 million","effective_date":"2026-03-03","event_type":"restructuring","headcount_text":"approximately 50% of the Company’s overall workforce","item_codes_triggered":["2.05"]},"claim":"Theravance Biopharma, Inc. announced a restructuring with charges of approximately $5 million to $7 million affecting R&D and G&A functions (approximately 50% of the Company’s overall workforce).","evidence_excerpt":"On March 3, 2026, the Company announced an organizational restructuring (the “Restructuring”), which is intended to reduce cost base by approximately 60% (or approximately $70 million) and expected to impact approximately 50% of the Company’s overall workforce. The Restructuring will be implemented over the next two quarters, with the Company expecting to incur approximately $5 million to $7 million in one-time cash severance costs related to the Restructuring.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-26-022572","anchor_url":"https://secwatch.observer/filing/0001104659-26-022572#claim-d9246ac14ae0aaac8a8523e6076bc8c927fb1ee5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465926022572/0001104659-26-022572-index.htm"},{"fact_type":"ma_transaction","fact_key":"7e14eb759d4625a88d5ed4acfb24e7c051177081","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2025-06-02T23:59:59+00:00","payload":{"action":"disposition","closing_date":"2025-05-30","consideration_text":"$225 million","counterparty":"GlaxoSmithKline Intellectual Property Development Limited","effective_date":"2025-05-30","item_codes_triggered":["2.01"]},"claim":"Theravance Biopharma, Inc. completed a disposition involving GlaxoSmithKline Intellectual Property Development Limited for $225 million (closed 2025-05-30).","evidence_excerpt":"ompany (“TBPH”) and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-25-055100","anchor_url":"https://secwatch.observer/filing/0001104659-25-055100#claim-7e14eb759d4625a88d5ed4acfb24e7c051177081","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465925055100/0001104659-25-055100-index.htm"},{"fact_type":"earnings_release","fact_key":"f69585588960026ed2f1380899bfeae74a5c9086","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $11.7 million","period_text":"the first quarter of 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":"Total revenue for the first quarter of 2024 was $14.5 million"},"claim":"Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.","evidence_excerpt":"Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-060536","anchor_url":"https://secwatch.observer/filing/0001104659-24-060536#claim-f69585588960026ed2f1380899bfeae74a5c9086","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/0001104659-24-060536-index.htm"},{"fact_type":"shareholder_vote","fact_key":"9654bfe900e330c1b7f6fbe6e747179262e01fa2","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Non-binding advisory resolution regarding compensation of named executive officers","proposal_type":"say_on_pay","votes_abstain_text":"2,683","votes_against_text":"332,345","votes_for_text":"35,205,714"},"claim":"Theravance Biopharma, Inc. shareholders approved Non-binding advisory resolution regarding compensation of named executive officers at the 2024-05-08 meeting.","evidence_excerpt":"Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company’s named executive officers was approved: For Against Abstain Broker Non- Votes Number of Shares Voted 35,205,714 332,345 2,683 3,952,947","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059338","anchor_url":"https://secwatch.observer/filing/0001104659-24-059338#claim-9654bfe900e330c1b7f6fbe6e747179262e01fa2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm"},{"fact_type":"shareholder_vote","fact_key":"f63969468a4f9be3cf158b9261cf12400dfb4df3","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024","proposal_type":"auditor_ratification","votes_abstain_text":"7,629","votes_against_text":"228,078","votes_for_text":"39,257,982"},"claim":"Theravance Biopharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.","evidence_excerpt":"Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 was ratified: For Against Abstain Broker Non- Votes Number of Shares Voted 39,257,982 228,078 7,629 N/A","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059338","anchor_url":"https://secwatch.observer/filing/0001104659-24-059338#claim-f63969468a4f9be3cf158b9261cf12400dfb4df3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3a8285349d7a0d271dc0dd6438c6b297c1f52fef","cik":1583107,"ticker":"TBPH","company_name":"Theravance Biopharma, Inc.","filed_at":"2024-05-09T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2024-05-08","outcome":"passed","proposal_text":"Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup","proposal_type":"director_election","votes_abstain_text":"635 (Eran Broshy); 435 (James Kelly); 9,536 (Laurie Smaldone","votes_against_text":"223,797 (Eran Broshy); 274,631 (James Kelly); 240,365 (Lauri","votes_for_text":"35,316,310 (Eran Broshy), 35,265,676 (James Kelly), 35,290,8"},"claim":"Theravance Biopharma, Inc. shareholders approved Election of Class I directors: Eran Broshy, James Kelly, Laurie Smaldone Alsup at the 2024-05-08 meeting.","evidence_excerpt":"Proposal One – Based on the following results of voting, the nominees listed below were elected Class I directors to serve as members of the Board until the Company’s Annual General Meeting held in 2026 and until their successors are duly elected and qualified: Nominees For Against Abstain Broker Non- Votes Eran Broshy 35,316,310 223,797 635 3,952,947 James Kelly 35,265,676 274,631 435 3,952,947 Laurie Smaldone Alsup 35,290,841 240,365 9,536 3,952,947","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-24-059338","anchor_url":"https://secwatch.observer/filing/0001104659-24-059338#claim-3a8285349d7a0d271dc0dd6438c6b297c1f52fef","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465924059338/0001104659-24-059338-index.htm"}]}